MedDevNews, Q3 2022
The effects of the market-wide contraction continued to be seen across multiple metrics in Q3 2022. Public market returns were again negative across all verticals, with the best performing sector of large diversified still down 11.9% for the year. Most sectors again underperformed the S&P 500, though Spine Orthopedics, CMOs, Large Diversified, and Lab Diagnostics exceeded the index. OEM M&A transaction activity was down relative to Q2 2022 and Q3 2021, while CMO M&A remained flat versus Q2 2022, at a level down significantly versus prior year numbers. Private financings rose for the quarter after over a year of declines. OEM disclosed value increased slightly but did not approach the highs of 2020 or 2021.